Published in
Elsevier, European Journal of Cancer, (96), p. 6-16
DOI: 10.1016/j.ejca.2018.03.012
Links
Tools
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Journal article published in 2018 by
Andreas Wicki 
,
Nicholas Brown,
Alexandros Xyrafas,
Vincent Bize,
Hanne Hawle,
Simona Berardi,
Nataša Cmiljanović,
Vladimir Cmiljanović,
Michael Stumm,
Saša Dimitrijević,
Richard Herrmann,
Vincent Prêtre,
Reto Ritschard,
Alexandar Tzankov,
Viviane Hess
and other authors.
,
Nicholas Brown,
Alexandros Xyrafas,
Vincent Bize,
Hanne Hawle,
Simona Berardi,
Nataša Cmiljanović,
Vladimir Cmiljanović,
Michael Stumm,
Saša Dimitrijević,
Richard Herrmann,
Vincent Prêtre,
Reto Ritschard,
Alexandar Tzankov,
Viviane Hess
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 